Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Kroesen, Michiel ^a,b   Büll, Christian ^a   Gielen, Paul R ^a   Brok, Ingrid C ^a   Armandari, Inna ^a   Wassink, Melissa ^a   Looman, Maaike W G ^a   Boon, Louis ^c   den Brok, Martijn H ^a   Hoogerbrugge, Peter M ^b,d   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EPIRUS Biopharmaceuticals Netherlands BV   (Netherlands)

^d Department of Radiation Oncology   (Netherlands)

Author keywords

Anti gd2 mAb therapy; histone deacytelase inhibitor; immunotherapy; myeloid derived suppressor cell; neuroblastoma

Indexed keywords

ABEXINOSTAT; ANTI GD2 MONOCLONAL ANTIBODY; BELINOSTAT; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; MONOCLONAL ANTIBODY; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IC50; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROBLASTOMA; NONHUMAN; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84976293012     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1164919     Document Type: Article

References (58)

1. J.M.Maris, M.D.Hogarty, R.Bagatell, S.L.Cohn. Neuroblastoma. Lancet 2007; 369:2106-20; PMID:17586306; 10.1016/S0140-6736(07)60983-0
2. K.K.Matthay, C.P.Reynolds, R.C.Seeger, H.Shimada, E.S.Adkins, D.Haas-Kogan, R.B.Gerbing, W.B.London, J.G.Villablanca. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27:1007-13; PMID:19171716; 10.1200/JCO.2007.13.8925
3. A.L.Yu, A.L.Gilman, M.F.Ozkaynak, W.B.London, S.G.Kreissman, H.X.Chen, M.Smith, B.Anderson, J.G.Villablanca, K.K.Matthay et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; 10.1056/NEJMoa0911123
4. N.Tarek, J.B.Le Luduec, M.M.Gallagher, J.Zheng, J.M.Venstrom, E.Chamberlain, S.Modak, G.Heller, B.Dupont, N.K.Cheung et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 2012; 122:3260-70; PMID:22863621; 10.1172/JCI62749
5. N.K.Cheung, I.Y.Cheung, K.Kramer, S.Modak, D.Kuk, N.Pandit-Taskar, E.Chamberlain, I.Ostrovnaya, B.H.Kushner. Key role for myeloid cells: Phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 2014; 135(9):2199-205; PMID:24644014; 10.1002/ijc.28851
6. M.Kroesen, D.Lindau, P.Hoogerbrugge, G.J.Adema. Immunocombination therapy for high-risk neuroblastoma. Immunotherapy 2012; 4:163-74; PMID:22394368; 10.2217/imt.11.169
7. O.Khan, N.B.La Thangue. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90:85-94; PMID:22124371; 10.1038/icb.2011.100
8. J.E.Bolden, W.Shi, K.Jankowski, C.Y.Kan, L.Cluse, B.P.Martin, K.L.MacKenzie, G.K.Smyth, R.W.Johnstone. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 2013; 4:e519; PMID:23449455; 10.1038/cddis.2013.9
9. N.Nalabothula, F.Carrier. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011; 3:145-55; PMID:21743813; 10.2217/epi.11.12
10. A.Muhlethaler-Mottet, R.Meier, M.Flahaut, K.B.Bourloud, K.Nardou, J.M.Joseph, N.Gross. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008; 7:55; PMID:18549473; 10.1186/1476-4598-7-55
11. F.Condorelli, I.Gnemmi, A.Vallario, A.A.Genazzani, P.L.Canonico. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153:657-68; PMID:18059320; 10.1038/sj.bjp.0707608
12. M.S.Finnin, J.R.Donigian, A.Cohen, V.M.Richon, R.A.Rifkind, P.A.Marks, R.Breslow, N.P.Pavletich. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401:188-93; PMID:10490031; 10.1038/43710
13. M.Duvic, J.Vu. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111-20; PMID:17594194; 10.1517/13543784.16.7.1111
14. M.Fouladi, J.R.Park, C.F.Stewart, R.J.Gilbertson, P.Schaiquevich, J.Sun, J.M.Reid, M.M.Ames, R.Speights, A.M.Ingle et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-9; PMID:20606092; 10.1200/JCO.2009.25.9119
15. R.C.Seeger, G.M.Brodeur, H.Sather, A.Dalton, S.E.Siegel, K.Y.Wong, D.Hammond. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111-6; PMID:4047115; 10.1056/NEJM198510313131802
16. J.F.Jacobs, H.van Bokhoven, F.N.van Leeuwen, C.A.Hulsbergen-van de Kaa, I.J.de Vries, G.J.Adema, P.M.Hoogerbrugge, A.P.de Brouwer. Regulation of MYCN expression in human neuroblastoma cells. BMC Cancer 2009; 9:239; PMID:19615087; 10.1186/1471-2407-9-239
17. W.A.Weiss, K.Aldape, G.Mohapatra, B.G.Feuerstein, J.M.Bishop. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16:2985-95; PMID:9214616; 10.1093/emboj/16.11.2985
18. T.Teitz, J.J.Stanke, S.Federico, C.L.Bradley, R.Brennan, J.Zhang, M.D.Johnson, J.Sedlacik, M.Inoue, Z.M.Zhang et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 2011; 6:e19133; PMID:21559450; 10.1371/journal.pone.0019133
19. M.Kroesen, S.Nierkens, M.Ansems, M.Wassink, R.J.Orentas, L.Boon, M.H.den Brok, P.M.Hoogerbrugge, G.J.Adema. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer 2014; 134:1335-45; PMID:24038106; 10.1002/ijc.28463
20. L.M.Carlson, A.Rasmuson, H.Idborg, L.Segerstrom, P.J.Jakobsson, B.Sveinbjornsson, P.Kogner. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 2013; 34:1081-8; PMID:23349014; 10.1093/carcin/bgt009
21. G.Santilli, I.Piotrowska, S.Cantilena, O.Chayka, M.D'Alicarnasso, D.A.Morgenstern, N.Himoudi, K.Pearson, J.Anderson, A.J.Thrasher et al. Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res 2013; 19:1116-25; PMID:23322899; 10.1158/1078-0432.CCR-12-2528
22. K.Movahedi, D.Laoui, C.Gysemans, M.Baeten, G.Stange, J.Van den Bossche, M.Mack, D.Pipeleers, P.In't Veld, P.De Baetselier et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; PMID:20570887; 10.1158/0008-5472.CAN-09-4672
23. R.A.Franklin, W.Liao, A.Sarkar, M.V.Kim, M.R.Bivona, K.Liu, E.G.Pamer, M.O.Li. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344:921-5; PMID:24812208; 10.1126/science.1252510
24. T.Lu, R.Ramakrishnan, S.Altiok, J.I.Youn, P.Cheng, E.Celis, V.Pisarev, S.Sherman, M.B.Sporn, D.Gabrilovich. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011; 121:4015-29; PMID:21911941; 10.1172/JCI45862
25. M.Kroesen, P.Gielen, I.C.Brok, I.Armandari, P.M.Hoogerbrugge, G.J.Adema. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 2014; 5:6558-72; PMID:25115382; 10.18632/oncotarget.2289
26. M.Kroesen, S.Nierkens, M.Ansems, M.Wassink, R.J.Orentas, L.Boon, M.H.den Brok, P.M.Hoogerbrugge, G.J.Adema. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer 2014; 134:1335-45; PMID:24038106; 10.1002/ijc.28463
27. K.Furukawa, W.Aixinjueluo, T.Kasama, Y.Ohkawa, M.Yoshihara, Y.Ohmi, O.Tajima, A.Suzumura, D.Kittaka. Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21. J Neurochem 2008; 105:1057-66; PMID:18194438; 10.1111/j.1471-4159.2008.05232.x
28. Y.Suzuki, M.Yanagisawa, T.Ariga, R.K.Yu. Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development. J Neurochem 2011; 116:874-80; PMID:21214566; 10.1111/j.1471-4159.2010.07042.x
29. M.Leidi, E.Gotti, L.Bologna, E.Miranda, M.Rimoldi, A.Sica, M.Roncalli, G.A.Palumbo, M.Introna, J.Golay. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182:4415-22; PMID:19299742; 10.4049/jimmunol.0713732
30. K.D.Grugan, F.L.McCabe, M.Kinder, A.R.Greenplate, B.C.Harman, J.E.Ekert, N.van Rooijen, G.M.Anderson, J.A.Nemeth, W.R.Strohl et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189:5457-66; PMID:23105143; 10.4049/jimmunol.1201889
31. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; 10.1038/nri3175
32. D.Canioni, G.Salles, N.Mounier, N.Brousse, M.Keuppens, F.Morchhauser, T.Lamy, A.Sonet, M.C.Rousselet, C.Foussard et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26:440-6; PMID:18086798; 10.1200/JCO.2007.12.8298
33. B.Petricevic, J.Laengle, J.Singer, M.Sachet, J.Fazekas, G.Steger, R.Bartsch, E.Jensen-Jarolim, M.Bergmann. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 2013; 11:307; PMID:24330813; 10.1186/1479-5876-11-307
34. R.Braster, T.O'Toole, M.van Egmond. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 2014; 65:28-37; PMID:23811299; 10.1016/j.ymeth.2013.06.020
35. L.A.Haile, J.Gamrekelashvili, M.P.Manns, F.Korangy, T.F.Greten. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol 2010; 185:203-10; PMID:20525890; 10.4049/jimmunol.0903573
36. J.I.Youn, S.Nagaraj, M.Collazo, D.I.Gabrilovich. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; 10.4049/jimmunol.181.8.5791
37. R.L.Ferris, E.M.Jaffee, S.Ferrone. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28:4390-9; PMID:20697078; 10.1200/JCO.2009.27.6360
38. L.Galluzzi, E.Vacchelli, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, J.Zucman-Rossi, L.Zitvogel, G.Kroemer. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; 10.4161/onci.1.1.17938
39. T.Simon, B.Hero, A.Faldum, R.Handgretinger, M.Schrappe, T.Klingebiel, F.Berthold. Long-term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11:21; PMID:21244693; 10.1186/1471-2407-11-21
40. C.K.Hahn, K.N.Ross, I.M.Warrington, R.Mazitschek, C.M.Kanegai, R.D.Wright, A.L.Kung, T.R.Golub, K.Stegmaier. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A 2008; 105:9751-6; PMID:18607002; 10.1073/pnas.0710413105
41. T.Liu, A.E.Tee, A.Porro, S.A.Smith, T.Dwarte, P.Y.Liu, N.Iraci, E.Sekyere, M.Haber, M.D.Norris et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A 2007; 104:18682-7; PMID:18003922; 10.1073/pnas.0705524104
42. M.Lodrini, I.Oehme, C.Schroeder, T.Milde, M.C.Schier, A.Kopp-Schneider, J.H.Schulte, M.Fischer, K.De Preter, F.Pattyn et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013; 41:6018-33; PMID:23625969; 10.1093/nar/gkt346
43. D.Lindau, P.Gielen, M.Kroesen, P.Wesseling, G.J.Adema. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138:105-15; PMID:23216602; 10.1111/imm.12036
44. R.Tao, E.F.de Zoeten, E.Ozkaynak, C.Chen, L.Wang, P.M.Porrett, B.Li, L.A.Turka, E.N.Olson, M.I.Greene et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-307; PMID:17922010; 10.1038/nm1652
45. T.Akimova, G.Ge, T.Golovina, T.Mikheeva, L.Wang, J.L.Riley, W.W.Hancock. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136:348-63; PMID:20478744; 10.1016/j.clim.2010.04.018
46. B.W.Bridle, L.Chen, C.G.Lemay, J.S.Diallo, J.Pol, A.Nguyen, A.Capretta, R.He, J.L.Bramson, J.C.Bell et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013; 21:887-94; PMID:23295947; 10.1038/mt.2012.265
47. P.Cheng, C.A.Corzo, N.Luetteke, B.Yu, S.Nagaraj, M.M.Bui, M.Ortiz, W.Nacken, C.Sorg, T.Vogl et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; 10.1084/jem.20080132
48. K.Movahedi, M.Guilliams, J.Van den Bossche, R.Van den Bergh, C.Gysemans, A.Beschin, P.De Baetselier, J.A.Van Ginderachter. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; 10.1182/blood-2007-07-099226
49. Y.Hamaguchi, Y.Xiu, K.Komura, F.Nimmerjahn, T.F.Tedder. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203:743-53; PMID:16520392; 10.1084/jem.20052283
50. N.Gul, L.Babes, K.Siegmund, R.Korthouwer, M.Bogels, R.Braster, G.Vidarsson, T.L.Ten Hagen, P.Kubes, M.van Egmond. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014; 124:812-23; PMID:24430180; 10.1172/JCI66776
51. S.Asgharzadeh, J.A.Salo, L.Ji, A.Oberthuer, M.Fischer, F.Berthold, M.Hadjidaniel, C.W.Liu, L.S.Metelitsa, R.Pique-Regi et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012; 30:3525-32; PMID:22927533; 10.1200/JCO.2011.40.9169
52. J.A.McEarchern, E.Oflazoglu, L.Francisco, C.F.McDonagh, K.A.Gordon, I.Stone, K.Klussman, E.Turcott, N.van Rooijen, P.Carter et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109:1185-92; PMID:17038522; 10.1182/blood-2006-07-034017
53. E.Oflazoglu, I.J.Stone, K.A.Gordon, I.S.Grewal, N.van Rooijen, C.L.Law, H.P.Gerber. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007; 110:4370-2; PMID:17909075; 10.1182/blood-2007-06-097014
54. P.Hubert, A.Heitzmann, S.Viel, A.Nicolas, X.Sastre-Garau, P.Oppezzo, O.Pritsch, E.Osinaga, S.Amigorena. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011; 71:5134-43; PMID:21697279; 10.1158/0008-5472.CAN-10-4222
55. D.D.Vo, R.M.Prins, J.L.Begley, T.R.Donahue, L.F.Morris, K.W.Bruhn, P.de la Rocha, M.Y.Yang, S.Mok, H.J.Garban et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009; 69:8693-9; PMID:19861533; 10.1158/0008-5472.CAN-09-1456
56. A.J.Christiansen, A.West, K.M.Banks, N.M.Haynes, M.W.Teng, M.J.Smyth, R.W.Johnstone. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 2011; 108:4141-6; PMID:21368108; 10.1073/pnas.1011037108
57. D.K.Kim, J.Y.Lee, J.S.Kim, J.H.Ryu, J.Y.Choi, J.W.Lee, G.J.Im, T.K.Kim, J.W.Seo, H.J.Park et al. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem 2003; 46:5745-51; PMID:14667227; 10.1021/jm030377q
58. A.P.Kozikowski, S.Tapadar, D.N.Luchini, K.H.Kim, D.D.Billadeau. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 2008; 51:4370-3; PMID:18642892; 10.1021/jm8002894